David Rees

Business Insights Analyst; Cardiovascular, Metabolic, Renal, and Hematological Disorders. Specializing in Osteoporosis.

[David Rees @DavidRees_DRG]

$RDUS Abaloparatide has failed to get CHMP negative opinion overturned. Good news for #Forteo and #Evenity (if approved)? Definitely. Good news for European patients needing anabolic osteoporosis drugs? Maybe not.

[David Rees @DavidRees_DRG]

Puma Biotechnology’s breast cancer therapy #Nerlynx (Neratinib) has just had its CHMP negative opinion overturned. Will abaloparatide be as lucky? $PBYI #CHMP #EMA #Tymlos #RDUS https://t.co/PwA8t8ijSO

[David Rees @DavidRees_DRG]

@Radius_Health #Tymlos failed to get approval in Europe. $RDUS have requested a re-evaluation. We’ve looked at the likelihood of getting this decision reversed. #Osteoporosis #CHMP #EMA #abaloparatide

[David Rees @DavidRees_DRG]

@trinh_pham13 FYI https://t.co/PP65bN57fI

[David Rees @DavidRees_DRG]

Alendronate shown to be cardioprotective. Could these results help explain the cv signal in the ARCH trial? Amen/UCB will be hoping they sway the regulators when deciding if to approve Evenity (romosozumab). $amgn $ucb
https://t.co/EsvELddVfb

[David Rees @DavidRees_DRG]

Puma Biotechnology’s breast cancer therapy #Nerlynx (Neratinib) has just its CHMP negative opinion overturned. Will abaloparatide be as lucky? $PBYI #CHMP #EMA #Tymlos #RDUS

[David Rees @DavidRees_DRG]

@Radius_Health #Tymlos failed to get approval in Europe. $RDUS have requested a re-evaluation. We’ve looked at the likelihood of getting this decision reversed. #Osteoporosis #CHMP #EMA #abaloparatide

[David Rees @DavidRees_DRG]

@ggreen_DRG @Amerron_DRG Puma Biotechnology’s breast cancer therapy #Nerlynx (Neratinib) is also in a similar boat. $PBYI #CHMP #EMA #breastcancer

[David Rees @DavidRees_DRG]

@trinh_pham13 Amgen/UCB still haven't resubmitted. I expect an FDA Class 2 re-submission, with a response date 6 months after the submission date.They submitted to the EMA in January so will hear back Jan 2019.

[Sanofi US @SanofiUS]

People of all races, religions and nationalities work at Sanofi every day to improve the lives of people around the world. While all pharmaceutical treatments have side effects, racism is not a known side effect of any Sanofi medication.

[David Rees @DavidRees_DRG]

Novel SLIT3 pathway involved in bone formation discovered. Found to promote blood vessel growth. With so few drugs in the osteoporosis pipeline, anything new is of promise. #osteoporosis #boneformation
https://t.co/4vUWHtCoN3

[Kerri Brown @itskerribrown]

Oh! I co-authored a #hemophilia article in #Nature Reviews Drug Discovery 🤗 it published May 21. Click on the link to read my and @ggreen_DRG’s take on the hemophilia drug market: https://t.co/kKBuLGNzeC #DRG

[David Rees @DavidRees_DRG]

WCO-IOF-ESCOE: Osteoporosis Conference Highlights. What were the major themes and stand-out talks? #OsteoCongress $AMGN #Prolia $LLY #Forteo $RDUS #Tymlos
https://t.co/SfL3XR4vi7

[David Rees @DavidRees_DRG]

What looks hot at the WCO-IOF-ESCEO this year? My guide to this year's osteoporosis conference #OsteoCongress
https://t.co/OgOZE8EMCO

[David Rees @DavidRees_DRG]

@trinh_pham13 Agreed,it's a smaller market,but not insignificant.About 3rd size of US. True that royalty revenues will be smaller, but they won't have the v. Expensive marketing costs.Osteo drugs released not approved in 1 region don't have good track record.Calcitonin&Strontium ranelate?

[David Rees @DavidRees_DRG]

CHMP given negative trend vote for Tymlos(abaloparatide). $RDUS say they will appeal, but with generic Forteo (2019) & $UCB $AMGN Evenity(romosozumab) possibly from 2019 is $RDUS running out of time in Europe? Will there be a negative halo affect in the US?

[David Rees @DavidRees_DRG]

If the CHMP are concerned about the risks CV risks for $RDUS Tymlos(abaloparatide), should $UCB and $AMGN be even more concerned for Evenity(romosozumab) in light of the CV signal seen in the ARCH study? https://t.co/H54pVLPJZi

[Max Stendahl @bosbizmax]

CHMP has explained why it rejected $RDUS abaloparatide, which FDA approved last year as Tymlos.